Oryzon Genomics S.A. Overview
Latest ROE for Oryzon Genomics S.A.: -1.97% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-1.97%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for ORY.MC is -1.97%. That is below the Healthcare sector average of 11.15%. Investors often review this figure alongside Oryzon Genomics S.A.'s historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ORY.MC currently prints -1.97% for ROE, while the sector average sits near 11.15%. That is roughly 117.7% below the sector mean. Large gaps often invite a closer look at Oryzon Genomics S.A.'s growth, margins, and balance sheet.
Return on Equity shows how effectively Oryzon Genomics S.A. converts resources into returns. At -1.97%, ORY.MC may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting ORY.MC's ROE (-1.97%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Oryzon Genomics S.A.'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
